JNJ•benzinga•
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Summary
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga